Dr Reddy's Labs unit inks drug discovery, development pact with EQRx

The parties would share both fundings for the discovery and development of the programmes and financials resulting from the commercialisation of any eventual drug candidates, Aurigene stated.

Published On 2022-07-05 06:01 GMT | Update On 2022-07-05 06:02 GMT

New Delhi: Aurigene Discovery Technologies, a unit of Dr. Reddy's Laboratories, on Monday said it has inked a drug discovery, development, and commercialisation partnership with US-based EQRx. The collaboration combines Aurigene's small molecule drug discovery platform and EQRx's business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.

Under the terms of the collaboration agreement, Aurigene and EQRx will collaborate on drug discovery, pre-clinical and clinical development, and commercialisation, Aurigene Discovery Technologies said in a statement.

Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory, and commercialisation efforts, it added.

The parties would share both fundings for the discovery and development of the programmes and financials resulting from the commercialisation of any eventual drug candidates, the company stated.

"This agreement with EQRx further validates Aurigene's proven expertise in the discovery and preclinical development of novel therapeutics and moves Aurigene forward into building a global oncology franchise participating in the end-to-end value chain," Aurigene CEO Murali Ramachandra said.

Read also: JB Chemicals acquires 4 pediatric brands from Dr Reddys

EQRx's Carlos Garcia noted that combined efforts will be made towards some of the most high-impact therapeutic targets across oncology and immune- inflammatory diseases.

"Given our mission, we believe these future programmes hold the potential to create important treatments for patients and drive meaningful savings for healthcare systems around the world," he added.

Aurigene is a clinical-stage biotech company based in Bangalore and Kuala Lumpur. Aurigene specializes in cancer and inflammatory disorders. Aurigene has fully integrated Drug Discovery & Development infrastructure from Hit Generation to Clinical Development.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Dr Reddy's Labs unit inks drug discovery, development pact with EQRx

The parties would share both fundings for the discovery and development of the programmes and financials resulting from the commercialisation of any eventual drug candidates, Aurigene stated.

Similar News

AbbVie gets European Commission nod for Elahere for Platinum-Resistant ovarian cancer

Indian Pharma Market grows at 6.8 percent in October, Chronic Therapies Dominate: IQVIA

Merck gets positive EU CHMP opinion for Keytruda plus Chemotherapy as first-line treatment for adult patients with unresectable non-eithelioid Malignant Pleural Mesothelioma

Ratio enters license, collaboration agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

AstraZeneca Tagrisso recommended for approval in EU by CHMP for patients with unresectable EGFR mutated lung cancer

Shilpa Pharma Lifesciences gets CEP from EDQM for API, Octreotide

Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic Colorectal Cancer

Drug trafficker wanted over cough syrup bottles seizure nabbed